SEARCH

Current Location: DOTmed News > Industry Headlines > This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

More Industry Headlines

Varian's seven year patent dispute comes to an end Company will pay about $35 million.

FDA OKs GE's new CT scanner Ideal for challenging cases.

MRI technique can help treat concussion patients Measures white brain matter damage.

Special report: Contrast media One size does not fit all.

What's the big-picture impact of HIT on health care? Q&A with thought leader Bipin Thomas.

ABT's compact biomarker generator comes to Russia Ideal for the growing Russian market.

ClearMRI gets FDA clearance for MRI adaptor New option to extend the life of MRI systems.

Physician payment data now available CMS releases records and AMA pushes back.

Sebelius steps down from HHS post Sylvia Mathews Burwell to succeed Sebelius.

Is there a viable future for proton therapy? Yes, but challenges remain.

IBA spins off radiopharmaceutical division

by Brendon Nafziger , DOTmed News Associate Editor
New York private equity firm SK Capital Partners bought a controlling stake in Ion Beam Applications S.A.'s radiopharmaceutical division, which is being spun off into its own company, IBA announced Monday. Under the terms of the new deal, SK Capital will own 60 percent of the new business, called IBA Molecular Imaging, and IBA will retain a 40 percent stake.

The transaction, expected to close in the second quarter, is valued at 180 million euros ($229 million). IBA said it expects to net 100 million euros ($127 million) from the deal after debt adjustments, although the sale will result in "significant exceptional loss" for 2011 accounts as the transaction "does not value the IBA radiopharmaceutical business at the level previously booked in its consolidated statements," the company said in a statement.

Story Continues Below Advertisement

Free Whitepaper: Are you giving up millions in costs & lost revenue?

Free White Paper Download: Five Costs You Don't Typically Associate with Clinical Engineering. Enhance your understanding. Download the complete white paper for free today.



IBA's stock shot up to a six-month high after the announcement, Reuters reports, rising more than 31 percent and hitting 6.31 euros per share in trading Monday.

Although IBA owns 40 percent of the new company, it will reap 60 percent of the profits for drugs currently under development, in recognition of its past R&D investments, the Belgian company said. In the pipeline are imaging tracers to help diagnose kidney disease and Alzheimer's disease. The development costs of the in-the-works drugs now would be shared equally, the companies said.

Renaud Dehareng, the radiopharmaceutical group's former president, will helm the new entity as CEO, IBA said.

IBA's molecular imaging group employs 1,000 people, has 57 nuclear medicine sites in Europe, the United States and Asia, and runs a manufacturing facility in France. It generates about 175 million euros ($222 million) in yearly revenues, IBA said.

In a separate announcement, IBA said Olivier Legrain, the current chief strategic officer, would be promoted to chief operating officer in preparation for when he takes the reins from CEO Pierre Mottet, who's stepping down in May. However, Mottet will continue with the company as vice-chairman of the board.

IBA, which also makes cyclotrons for proton therapy treatments, is headquartered in Louvain-la-Neuve, Belgium.

Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.

You Must Be Logged In To Post A Comment

Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2014 DOTmed.com, Inc.
ALL RIGHTS RESERVED